{
    "clinical_study": {
        "@rank": "19931", 
        "acronym": "D-LITE", 
        "arm_group": {
            "arm_group_label": "Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir", 
            "arm_group_type": "Experimental", 
            "description": "Pegylated Interferon Lambda 180 \u03bcg Solution, Subcutaneous Once weekly for 12 weeks;\nRibasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing \u2265 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg \u2265 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;\nDaclatasvir 60 mg oral tablet Once daily for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "Substudy C: The purpose of this substudy is to determine whether Lambda combined with\n      Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment na\u00efve subjects with\n      genotype 1b chronic HCV infection"
        }, 
        "brief_title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic Hepatitis C, Genotype 1\n\n          -  HCV RNA >100,000 IU/mL at screening;\n\n          -  Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen\n             (HBsAg);\n\n          -  Liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and\n             will be capped at approximately 10%\n\n        Exclusion Criteria:\n\n          -  Any evidence of liver disease other than HCV;\n\n          -  Co-infection with HIV;\n\n          -  Diagnosed or suspected hepatocellular carcinoma;\n\n          -  Medical history or laboratory value abnormalities that would prohibit the use of\n             Pegylated Interferon Alpha-2a or Ribavirin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795911", 
            "org_study_id": "AI452-008 (Substudy Part C)", 
            "secondary_id": "2010-022568-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir", 
                "intervention_name": "Pegylated Interferon Lambda", 
                "intervention_type": "Biological", 
                "other_name": "BMS-914143"
            }, 
            {
                "arm_group_label": "Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir", 
                "intervention_name": "Ribasphere", 
                "intervention_type": "Drug", 
                "other_name": "Ribavirin"
            }, 
            {
                "arm_group_label": "Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir", 
                "intervention_name": "Daclatasvir", 
                "intervention_type": "Drug", 
                "other_name": "BMS-790052"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 4, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Eric Lawtiz, Site 023", 
                "phone": "210-253-3426"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78215"
                }, 
                "name": "Alamo Medical Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment na\u00efve Subjects", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For participation information at a USA site use a phone number below. For Site information outside USA please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Australia: National Health and Medical Research Council", 
                "New Zealand: Medsafe", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: Ministry of Health", 
                "Italy: National Bioethics Committee", 
                "Italy: National Institute of Health", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HCV = Hepatitis C virus; GT = Geno Type; RNA = Ribonucleic acid; LLOQ = Lower limit of quantitation", 
            "measure": "Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA < LLOQ target detected or not detected", 
            "safety_issue": "No", 
            "time_frame": "Post-treatment Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "eRVR = Extended rapid virologic response", 
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA < LLOQ target not detected", 
                "safety_issue": "No", 
                "time_frame": "At Week 4 and Week 12"
            }, 
            {
                "description": "Hb = Hemoglobin; ANC = Absolute neutrophil count", 
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3, and/or thrombocytopenia as defined by platelets < 50,000 mm3) on treatment", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or chills or pain)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA < LLOQ target detected or not detected", 
                "safety_issue": "No", 
                "time_frame": "Post-treatment follow-up Week 24"
            }, 
            {
                "measure": "Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12 and post-treatment weeks 4, 12, 24, 36 and 48"
            }, 
            {
                "measure": "Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12 and post-treatment weeks 4, 12, 24, 36 and 48"
            }, 
            {
                "measure": "Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }, 
            {
                "measure": "Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks)", 
                "safety_issue": "Yes", 
                "time_frame": "On-treatment Weeks 1, 2, 4, 8, and 12"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}